0
Original Research: INTERVENTIONAL PULMONOLOGY |

Biological Lung Volume Reduction*A New Bronchoscopic Therapy for Advanced Emphysema

John Reilly, MD, FCCP; George Washko, MD; Victor Pinto-Plata, MD, FCCP; Eduardo Velez, MD; Lawrence Kenney, MD, FCCP; Robert Berger, MD; Bartolome Celli, MD, FCCP
Author and Funding Information

*From the Pulmonary and Critical Care Division (Drs. Reilly and Washko), Brigham and Women’s Hospital, Boston, MA; the Department of Surgery (Dr. Berger), Harvard Medical School, Boston, MA; and Pulmonary Department (Drs. Pinto-Plata, Velez, Kenney, and Celli), Caritas-St. Elizabeth’s Medical Center, Boston, MA.

Correspondence to: John Reilly, MD, FCCP, Brigham and Women’s Hospital, Pulmonary/Critical Care Medicine, 75 Francis St, Boston, MA 02115-6110; e-mail: jreilly@partners.org



Chest. 2007;131(4):1108-1113. doi:10.1378/chest.06-1754
Text Size: A A A
Published online

Background: Biological lung volume reduction (BLVR) using biological reagents to remodel and shrink damaged regions of lung has previously been accomplished in sheep with experimental pulmonary emphysema. This report summarizes the initial clinical experience including a 3-month follow-up using this technique in humans.

Methods: An open-label phase 1 trial designed to evaluate the safety of BLVR in patients with advanced heterogeneous emphysema enrolled six patients. Of these, three patients received unilateral treatment at two pulmonary subsegments (group 1) and three patients received unilateral treatment at four pulmonary subsegments (group 2). The incidence of adverse events and changes in pulmonary function test results, symptoms, and exercise capacity were evaluated.

Results: The mean (± SD) age of the six men enrolled in the study was 66 ± 5.7 years (age range, 57 to 73 years). BLVR was well tolerated in both treatment groups and was not associated with any serious complications. All patients were discharged from the hospital on posttreatment day 1. Although the primary purpose of the study was to examine safety, improvements were observed in mean vital capacity (+7.2 ± 9.5%; range, −2% to + 19%), mean residual volume (RV) [−7.8 ± 8.5%; range, + 1% to −22%], mean RV/total lung capacity ratio (−6.6 ± 4.7%; range, −1% to −15%), mean 6-min walk distance (+14.5 ± 18.5%; range, 0 to + 51%), and in mean dyspnea score. On average, group 2 patients experienced greater benefit from BLVR than group 1 patients, suggesting a dose-response pattern.

Conclusions: Preliminary results indicate that BLVR can be safe and may produce benefits in appropriately selected patients with advanced heterogeneous emphysema.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543